Ascentage Pharma (AAPG) | Stock Overview & Key Data
Ascentage Pharma Performance Comparison
Stock Range
Today's Range
Low: $40.00
High: $41.38
on July 18, 2025
52 Week Range
Low: $16.50
High: $43.58
on January 24, 2025
on July 3, 2025
All-Time High: $43.58 on July 3, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$3.4B
EPS
-0.75
P/E Ratio (TTM)
N/A
Forward P/E
40.23
P/B Ratio
45.65
PEG Ratio
N/A
Div. Yield
N/A
ROE
-235.32%
Beta
0.782
Debt to Equity
608.58
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-361.23%
Profit Margin
-41.34%
Returns and Earnings
Return on Assets (TTM)
-9.25%
Return on Equity (TTM)
-235.32%
EBITDA
$-41.7M
Net Income (TTM)
$-56.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.43
Quarterly Revenue Growth (YoY)
97.90%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ascentage Pharma AAPG | 3.36B Mid-cap | 5.62% | 12.57% | 111.24% | 132.39% | 132.39% | 127.96% | 127.96% | 127.96% |
| Vertex VRTX | 118.97B Large-cap | -1.93% | 2.54% | -3.71% | 7.46% | 13.32% | -5.76% | 65.28% | 66.35% |
| Regeneron REGN | 59.38B Large-cap | -4.44% | 5.63% | -3.38% | -21.12% | -24.14% | -48.29% | -6.16% | -9.68% |
| BridgeBio Pharma BBIO | 8.92B Mid-cap | 0.09% | 16.28% | 38.79% | 28.91% | 64.93% | 78.47% | 360.49% | 54.51% |
| Blueprint Medicines BPMC | 8.36B Mid-cap | 0.10% | 0.96% | 52.86% | 17.64% | 48.46% | 12.60% | 149.54% | 73.38% |
| Bio-Techne TECH | 7.92B Mid-cap | -3.92% | 3.77% | 9.49% | -33.94% | -27.22% | -29.38% | -41.32% | -21.08% |
Ownership & Short Interest
Insider Ownership
0.00%
Institutional Ownership
0.27%
Shares Short
10K
Short Ratio
0.74
Short % of Shares Outstanding
0.01%
Average 10-Day Volume
11K
Average 90-Day Volume
13K
Ascentage Pharma Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ascentage Pharma would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is AAPG's 52-week high and low?
- In the last 52 weeks, Ascentage Pharma reached a high of $43.58 (on July 3, 2025) and a low of $16.50 (on January 24, 2025).
- What is the market cap and P/E ratio for AAPG?
- Curious about Ascentage Pharma's size and valuation? Its market capitalization stands at 3.36B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is 40.23.
- Does AAPG pay dividends? If so, what's the yield?
- As for dividends, Ascentage Pharma isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ascentage Pharma's main competitors or similar companies to consider before investing?
When looking at Ascentage Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX118.97B Healthcare Biotechnology -5.76% 65.28% Regeneron
REGN59.38B Healthcare Biotechnology -48.29% -6.16% BridgeBio Pharma
BBIO8.92B Healthcare Biotechnology 78.47% 360.49% Blueprint Medicines
BPMC8.36B Healthcare Biotechnology 12.60% 149.54% Bio-Techne
TECH7.92B Healthcare Biotechnology -29.38% -41.32% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ascentage Pharma Group International ADR? (e.g., ROE, Debt/Equity)
- To get a sense of Ascentage Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -235.32%, the Debt to Equity ratio from the most recent quarter is 608.58, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for AAPG?
- Looking at Ascentage Pharma's growth, its revenue over the trailing twelve months (TTM) was $137M. Compared to the same quarter last year (YoY), quarterly revenue grew by 97.90%, and quarterly earnings saw a YoY growth of N/A.
- How much of AAPG stock is held by insiders and institutions?
- Wondering who owns Ascentage Pharma stock? Company insiders (like executives and directors) hold about 0.00% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.27%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.